MDB Capital Holdings, LLC

PatentVest, a division of MDB Capital Holdings, announced its presence at Planet MicroCap Las Vegas on June 17. The firm will discuss how companies can transform intellectual property from a legal function into a strategic business asset, supporting enterprise value creation and long-term growth. PatentVest will also outline its vision for the future of intellectual property services through AI-native workflows and outcome-based patent prosecution, aiming to improve efficiency and strengthen patent quality.

PatentVest, a division of MDB Capital Holdings, announced the release of its report, "The Muscle Problem: How Myostatin Could Expand the GLP-1 Opportunity." The study analyzes the emerging muscle-preservation category in obesity therapeutics, identifying 20 programs in development. It highlights strategic acquisitions by major pharmaceutical companies and suggests that these therapies will enhance GLP-1 treatment outcomes by improving body composition, creating new partnering, licensing, and IP opportunities.

MDB Capital Holdings, LLC announced that its CEO & Co-Founder, Chris Marlett, will present at the Planet MicroCap Las Vegas 2026 conference on June 17, 2026. Additionally, PatentVest, MDB's wholly-owned subsidiary, and MDB-funded company Buda Juice will also present at the conference. The presentations will provide overviews of their respective businesses and include live Q&A sessions.

PatentVest, a division of MDB Capital Holdings, announced the launch of a new Case Studies section on its website. The inaugural case study features Docana, an artificial intelligence company, detailing how PatentVest provided strategic IP guidance. This included freedom-to-operate analysis, competitive intelligence, and strategic IP positioning within the complex and rapidly evolving AI patent landscape. The new section aims to showcase real-world examples of strategic IP leadership and innovation management.

MDB Capital Holdings reported a net loss attributable to the company of $(6.74) million for the three months ended March 31, 2026, a slight increase from $(6.59) million in the prior year. Total operating income significantly decreased to $44 thousand from $828 thousand, primarily due to higher unrealized losses on investment securities. The company also experienced a substantial increase in net cash used in operating activities and a decrease in total assets and cash balances.

PatentVest, a division of MDB Capital Holdings, has released a new report titled "The Triple-Agonist Race," providing a strategic analysis of the rapidly evolving obesity-drug landscape. The report highlights the market's transition beyond first-generation GLP-1 therapies, emphasizing the growing importance of intellectual property positioning, delivery systems, and long-term market control. It identifies 27 global triple-agonist programs and discusses how IP strategy and platform design will define the next phase of competition.

PatentVest released its latest "PatentVest Pulse" report, titled "The Last 20%: Retatrutide, the Glucagon Paradox, and the Race to Own Surgery-Level Weight Loss Without Surgery." The report analyzes the intellectual property landscape of weight loss drugs, highlighting Eli Lilly's retatrutide achieving 28.7% mean weight loss. It emphasizes that the focus is shifting from drug development to controlling the IP, mapping the full pipeline, deal layers, and IP structures that will define value capture in this competitive market.